“The signing of the exclusive license agreement and the launch of a new collaboration for the discovery of new compounds against high-value oncology targets represent a natural expansion of our strategic partnership with @IpsenGroup" Claude Larose-VP Business Development @IRICoR_
© 2008-2023 IRICoR